◆ 會議時間：2024年4月11日至13日
◆ 會議地點：美國 帕薩迪納
◆ 會議簡介：
2024年第5屆世界皮膚淋巴瘤大會(WCCL)將于2024年4月11日至13日在美國加利福尼亞州帕薩迪納舉行，會議由國際皮膚淋巴瘤學會(ISCL)組織。大會將為所有參與者（基礎科學家，皮膚科醫生，血液學家，臨床腫瘤學家，皮膚病理學家，放射腫瘤學家等）提供了一個重要的跨學科交流平臺，不僅可以分享最新動態和最新的研究進展，還可以討論皮膚淋巴瘤實踐中的挑戰。大會科學計劃將對基礎、轉化和臨床研究的最新進展提供全面的創新的概述，還將討論在皮膚淋巴瘤的診斷、實踐和管理方面的最新進展，促進對患者提供最高標準的護理和支持。WCCL每兩年舉辦一次。
國際皮膚淋巴瘤協會(ISCL)是一個非營利性的國際性組織，于1992年在紐約召開的世界皮膚病學大會上成立。ISCL的宗旨是增加對皮膚淋巴增生和相關疾病的認識；通過組織會議來宣促進科學信息的傳播；促進臨床醫生、科學家和區域或國家團體之間的合作；就皮膚淋巴瘤的診斷、管理和治療達成共識。未經許可禁止復制摘錄轉載本站任何內容-國際醫學會議網（lingyuint.com）.
5th World Congress of Cutaneous Lymphomas (5WCCL)
Date: April 11-13, 2024
Venue: Pasadena, California, USA
Sponsored by: International Society for Cutaneous Lymphomas (ISCL)
On behalf of: United States Cutaneous Lymphoma Consortium (USCLC) and European Organisation for Research and Treatment for Cancer-Cutaneous Lymphoma Task Force (EORTC CLTF)
Organized by: City of Hope
摘要征文投稿：
KEY DATES
| November 15, 2023 |
Submission Deadline |
| Late-December 2023 |
Acceptance?Notifications via email |
| January?15, 2024? ?? |
Withdrawal Deadline |
| Late-January 2024? |
Abstracts Added to Online Schedule |
| February 2, 2024 |
Early Bird Registration Deadline |
| April 11-13, 2024 |
Presentation at the 5th World Congress of Cutaneous Lymphomas |
點此提交摘要>>>Submit Abstract>>>
FOCUS AREAS INCLUDE?
- Classification/Epidemiology/Prognostic Factors
- Cutaneous Lymphoma International Consortium – PROCLIPI Studies
- Biologic Insights
- Pathogenesis/Biomarkers
- Tumor Microenvironment
- Therapeutics/Preclinical Studies
- Quality of Life/Patient-Reported Outcomes?
- Challenging Cases of Cutaneous Lymphomas
- Leading-Edge Research and Future Directions of Cutaneous Lymphomas?
SUBMIT YOUR SCIENTIFIC RESEARCH
As you prepare for your abstract submission, please make sure to review the Abstract Reference Guidelines below and make note of the following details:
- Abstracts may ONLY be submitted online.
- There are no restrictions on the number of abstracts you may submit.
- Science only
- Abstracts may NOT be about products or lines of business.
- 500 word limit for body of Abstract
- No submission extensions will be granted.
AUTHOR & SUBMISSION ELIGIBILITY
As you prepare for your abstract submission, please make note of the following eligibility criteria:
- The Congress?will not accept abstract submissions from authors and/or co-authors who are employees of pharmaceutical, biotechnology, or medical technology companies.
- Authors of all accepted abstracts (oral or poster) are expected to?present at the Congress, and therefore, must pay the registration fee to attend.?
ABSTRACT SELECTION PROCESS & PRESENTATIONS
All abstracts are subject to an anonymized peer-review by members of the 5th World Congress of Cutaneous Lymphomas?Scientific Committee.?
All reviewers, session planners and invited faculty will be required to disclose all financial relationships through the online system, helping to ensure high-quality, unbiased presentations and compliance with CME regulations. In addition, all authors must disclose all financial relationships during the submission process before their abstract will be considered and graded.
Priority for oral presentations will be given to papers not previously presented in international conferences or published in the literature.
ABSTRACT SUBMISSION REQUIREMENTS
As you prepare for your abstract submission, please make note of the following requirements and instructions.
Word Limit:?There is a limit of 500 words for abstract body submission.?
Title:?The title should be entered in mixed case (upper and lower-case letters). DO NOT enter the title in all capital or all lower-case letters. Abbreviations may not be used in the title, unless it follows the full name.
Abstract Body:
Include the following:
STUDIES
INTRODUCTION:?The introduction should be 2 or 3 brief sentences describing the objectives of the study.
METHODS:?A description of the methods used to conduct the study must be included (i.e., retrospective chart review, prospective trial). Detailed descriptions of laboratory techniques should not be included. Do not mention the institution where the work was performed in the body or title of the abstract.
RESULTS:?The results should occupy one-half to two-thirds of the abstract, and specific data necessary to evaluate the abstract should be included. If there is concern that additional data would enhance the abstract, then please strongly consider including it. Statements such as "data will be discussed at the presentation" are grounds for disqualification.
CONCLUSION:?The conclusion should be no more than 2 or 3 sentences regarding the significance of the results in the context of the original objectives.
CASE REPORTS
INTRODUCTION:?The introduction should be 2 or 3 brief sentences describing the case's relevance and importance or what was challenging about it.?
CASE REPORT:?A description of the patient's history and details, treatment, patient's progress and outcome.?
DISCUSSION:?The discussion should be no more than 2 or 3 sentences that address why decisions were made and what is interesting or noteworthy about the case. Include lessons learned.?
Questions to address in the abstract:
1. Why was the study conducted/case reported?
2. How was the study conducted/case reported?
3. What were the results of the study/case?
4. What is the importance of the results?
Learning Objective:?Your learning objective should be a clear, concise statement of what participants should be able to do as a result of the CME activity.
Table or Image:?You may add one table OR one image to your abstract (not both). Characters will not be deducted from the total character count for tables and images.?
Presentation Type:?If selected, you will be notified if your presentation will be Oral or Poster.
Disclosures:?All authors and presenters must disclose any conflicts of interest and acknowledge any support from commercial interests for studies relating to the abstract. All authors and co-authors must agree with the abstract content to be considered for presentation.?Identify investigational products or off-label uses of products regulated by the US FDA at first mention and where appropriate in the content, using generic names as opposed to trade names.
CONFLICT OF INTEREST POLICY As required by the Accreditation Council for Continuing Medical Education (ACCME)?Standards for Integrity and Independence?in Accredited Continuing Education, all educational planners, presenters, instructors, moderators, authors, reviewers and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with an ineligible company (the ACCME defines an “ineligible company” as any entity producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients) that have occurred within the past 24 months. The ACCME considers financial relationships to create conflicts of interest when individuals have both a financial relationship with an ineligible company and the opportunity to affect the content of CME about the products or services of that ineligible company. All identified conflicts of interest must be resolved, and the educational content vetted for fair balance, scientific objectivity and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off label; experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. ACCME does not consider providers of clinical service directly to patients to be ineligible companies.
注冊費：
| Registrant Type |
Early Bird Registration*
(Before February 2, 2024) |
Regular Registration
(After February 2, 2024) |
| ISCL Member** |
$350 |
$450 |
| Non-Member |
$500 |
$550 |
| Student/Trainee |
$250 |
$250 |
| Patient/Patient Caregiver?(No CME Credit) |
$100 |
$100 |
| City of Hope Staff |
$300 |
$300 |
| Industry/Commercial Employee Attendee***? |
If you are interested in attending as a Industry/Commercial Employee please contact us at?cme@coh.org |
If you are interested in attending as a Industry/Commercial Employee please contact us at cme@coh.org |
| Congress Dinner Ticket (Attendee) |
$65 |
$65 |
| Congress Dinner Ticket (Guest) |
$150 |
$150 |
Registration Fee: Registration fee includes all Congress sessions, CME Credit (if applicable), meals (breakfast and lunch), refreshment breaks and Congress Welcome Reception on Thursday, April 11, 2024****
Additional Fee:?Congress Dinner on Friday, April 12, 2024 is?not?included in the registration fee, and would require a purchased ticket to attend. Attendee and Guest pricing available.?
Cancellation Policy:?Early Bird Registrations are nonrefundable. Refund requests must be submitted in writing and postmarked no later than Friday, February 9, 2024. A?$50 processing fee will be applied for all refunds. Requests postmarked after Friday, February 9, 2024, will not be honored. All refunds will be processed 30 days after the meeting concludes. In the event of unforeseeable circumstances that lead to the cancellation by the congress organizers, all registration fees will be fully refunded.
◆ 參會對象：醫生、醫院科室主任/副主任、住院醫師、醫院管理者、醫護人員以及從事該領域研究的科學家、研究人員、醫藥企業代表等等。
|
